Medicines & supplements – Current GIS Alerts 2026
Found 791 alerts in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
BENZACNE
A quality defect of the product was found regarding the gel appearance and active substance content, resulting from a defect of the immediate packaging, which may lead to improper quality and performance of the product. Potential effects: lack of treatment efficacy or unpredictable drug action.
BENODIL
A quality defect was identified consisting of out-of-specification results for the parameter of budesonide-related substances content, which may indicate an improper impurity profile and lack of compliance with quality requirements. Potential effects: possible reduced treatment efficacy or increased risk of adverse reactions.
BENODIL
Out-of-specification results were found in archival samples tested by the manufacturer, regarding the parameter of budesonide-related substances content, which means failure to meet established quality requirements. Potential effects: possible lack of treatment efficacy or unforeseen adverse reactions.
PRESARTAN
Impurities of N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) were detected in the active substance Losartanum kalicum from the manufacturer Zhejiang Huahai Pharmaceutical Co. Ltd. Potential effects: possible carcinogenic effects and health risks with long-term use.
PRESARTAN H
Detected nitrosamine-group impurities (NDMA and NDEA) in the active substance losartan potassium, which may affect human health and life, even though the levels do not exceed acceptable limits. Potential effects: possible carcinogenic effects and health complications with long-term use.
PRESARTAN H
The risk may be caused by the presence of nitrosamine-group contaminants in the active substance contained in these medicinal products, which may affect human health and life. Potential effects: possible carcinogenic effects, chronic health risk, potential complications with long-term use.
PRESARTAN
This risk may be caused by the presence of nitrosamine-group impurities in the active substance contained in the above-mentioned medicinal products, which may affect human health and life. Potential effects: possible carcinogenic effects and health complications during long-term use.
KORZEŃ ARCYDZIĘGLA
Failure to meet quality requirements of the medicinal product was found due to the presence of disqualifying features, which makes a potential risk to patients’ health or life plausible. Potential effects: lack of efficacy, possible adverse effects or health complications.
GLICEROL
Out-of-specification results were found for aldehydes, sugars, impurity A and related substances during stability testing of batch 01916, which makes a potential threat to the quality and safety of the medicinal product plausible. Potential effects: lack of efficacy or unforeseen adverse reactions.
FENSPOGAL
Unfavourable benefit-risk ratio for the active substance fenspiride, causing a potential, real and highly probable risk to patients' health or life, justifying immediate suspension and prohibition of placing the product on the market. Potential effects: serious adverse reactions, complications, life‑threatening events.
EURESPAL
Unfavourable benefit–risk balance for the active substance fenspiride; potential public health risk. The French agency (ANSM) initiated an urgent EU review. Potential effects: risk to health or life.
EUREFIN
Unfavorable benefit-risk ratio of the active substance fenspiride, leading to withdrawal of the reference product and initiation of an EU review. Potential effects: serious adverse reactions, risk to health or life.
EURESPAL
Unfavourable benefit–risk balance of the active substance fenspiride, which may pose a public health risk. Potential effects: deterioration of health, complications, life‑threatening risk.
EURESPAL
Unfavorable benefit-risk ratio of the active substance fenspiride; an EU re-evaluation procedure was initiated. Potential effects: serious adverse reactions, risk to health or life.
EURESPAL
Unfavorable benefit-risk ratio of the active substance fenspiride; an urgent EU reassessment procedure was initiated. Potential effects: adverse reactions, health complications.
PULNEO
An unfavorable benefit–risk balance was identified for the active substance fenspiride, considered a potential threat to patients’ health or life, requiring immediate suspension of all product batches from the market. Potential effects: health complications, possible severe reactions, life‑threatening risk.
PULNEO
An unfavorable benefit-risk balance was found for the active substance fenspiride, indicating a potential risk to patients’ health or life that required immediate suspension of the medicinal product from the market. Potential effects: serious adverse reactions, risk to health or life, possible complications.
PULNEO O SMAKU COLI
An unfavourable benefit-risk balance was identified for the active substance fenspiride, which may represent a real and highly probable risk to patients’ health or life. Potential effects: serious adverse reactions, risk to health or life.
FOSIDAL O SMAKU POMARAŃCZOWYM
An unfavorable benefit-risk ratio was identified for the active substance fenspiride, posing a potential threat to patients’ health or life, justifying immediate suspension of marketing and a temporary ban on placing the product on the market. Potential effects: serious adverse reactions, threat to health or life.
PULNEO O SMAKU COLI
An unfavourable benefit-risk ratio for the active substance fenspiride, potentially posing a risk to patients’ health or life, with the probability of harm to a person considered significant. Potential effects: serious adverse reactions, complications, threat to health or life.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.